Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Chimeric Antigen Receptor (CAR) T‐cell Therapy for People With Relapsed or Refractory Diffuse Large B‐cell Lymphoma." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431170/all/Single_dose_oral_dihydrocodeine_for_acute_postoperative_pain:_Cochrane_systematic_review. Accessed 28 March 2024.
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431170/all/Single_dose_oral_dihydrocodeine_for_acute_postoperative_pain:_Cochrane_systematic_review. Accessed March 28, 2024.
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431170/all/Single_dose_oral_dihydrocodeine_for_acute_postoperative_pain:_Cochrane_systematic_review
Chimeric Antigen Receptor (CAR) T‐cell Therapy for People With Relapsed or Refractory Diffuse Large B‐cell Lymphoma [Internet]. In: Cochrane Abstracts. [cited 2024 March 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431170/all/Single_dose_oral_dihydrocodeine_for_acute_postoperative_pain:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
ID - 431170
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431170/all/Single_dose_oral_dihydrocodeine_for_acute_postoperative_pain:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -